Short answer
Inogen Inc (INGN) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Completed sale of U.S. oxygen rental business to Rotech on November 2, 2026.
Inogen Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Completed sale of U.S. oxygen rental business to Rotech on November 2, 2026
- Assets transferred: specified on-rent and on-hand inventory plus related patient records
- Purchase price up to approximately $24.8 million, subject to post-closing reconciliation
- Six-installment payment structure, creating future cash receipts rather than immediate full proceeds
- Transaction exits Inogen’s U.S. rental operations, shifting focus away from that business segment
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026, announced November 5, 2026
- Press release includes update on completed sale of Inogen’s U.S. rental business
- Investors should review Exhibit 99.2 for financial figures and transaction details
Item 5.02 · Departure/Election of Directors or Officers
- Andy Reding appointed President, CEO and Class III director through 2029, replacing Kevin Smith effective October 30, 2026
- No COO successor planned, concentrating operating responsibilities under the new CEO
- Compensation: $700,000 salary, 100% target bonus, $300,000 signing bonus
- Equity package: 337,500 shares, split equally between time-based RSUs and performance-based PSUs, targeted for 2027 grants
- Severance exposure: 24 months’ salary, plus target bonus during the change-of-control period; Smith separation terms remain pending disclosure
Item 7.01 · Regulation FD Disclosure
- Press release announces completion of Inogen’s previously disclosed U.S. rental business sale
- Transaction marks exit from the U.S. rental business, affecting revenue mix and operating strategy
- Investors should review the Item 2.02 press release for transaction proceeds and financial impact
Item 8.01 · Other Events
- Board proposing annual director elections, replacing the classified board structure at the 2027 annual meeting
- Charter declassification previously won over 99% of votes cast, but failed the 66 2/3% outstanding-share threshold
- Supermajority voting requirements targeted for elimination, potentially lowering approval barriers for future governance changes
- Cost reduction program follows U.S. rental-business divestiture, targeting approximately $20 million in annualized savings
- Approximately half of savings expected in fourth-quarter 2026, with remainder realized throughout 2027; restructuring charges remain unestimated
Item EX-99.1 · Exhibit EX-99.1
- COO Andy Reding appointed President, CEO, and director, succeeding Kevin Smith
- Leadership change signals Board push to improve execution and restore sustainable, profitable growth
- Reding brings respiratory-care and medical-device commercialization experience from Viant Medical and Hillrom Respiratory Health
- Reding led a central role in the Rotech divestiture, supporting Inogen’s shift toward a streamlined commercial model
- Third-quarter 2026 results, for the period ended September 30, scheduled separately with a 5:00 p.m. ET investor call
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $77.2M, down 2.4% YoY, with U.S. growth 3.8% offset by international sales weakness
- Adjusted loss $0.4M versus $1.2M earnings, while GAAP loss widened to $14.8M, including a $10.6M impairment charge
- Rental divestiture completed for up to $24.8M, simplifying operations but shifting results to continuing operations
- $20M annualized cost reduction program targeted by end-2027, supporting profitability but requiring execution
- Cash and securities $97.7M, no debt, with share repurchase authorization increased $15M to $45M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inogen Inc 8-K filings
Get the next INGN 8-K as it lands
Follow INGN for push alerts, or ask the research agent what this filing means.